LuciDasa 50mg, Dasatinib Tablets

Dasatinib, a strong tyrosine kinase inhibitor, is marketed under the LuciDasa 50mg name and is mainly used to treat specific leukemia types. Dasatinib targets specific molecular abnormalities in cancer cells, offering a more targeted approach compared to traditional chemotherapy. LuciDasa is marketed in India and is typically prescribed for patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

What is LuciDasa 50mg (Dasatinib)?

Dasatinib is an oral medication that inhibits the activity of several tyrosine kinases, including BCR-ABL and Src family kinases.The development and survival of cancer cells are significantly influenced by these kinases. Dasatinib aids in regulating the growth of cancerous cells in CML and Ph+ ALL by inhibiting these enzymes.

Mechanism of Action

Dasatinib functions as an ATP-competitive inhibitor, binding to the ATP-binding site of the BCR-ABL fusion protein and other tyrosine kinases. This binding prevents the phosphorylation of downstream signaling molecules essential for cell division and survival, leading to apoptosis (programmed cell death) of the malignant cells. Its ability to inhibit multiple kinases contributes to its efficacy in treating resistant or intolerant cases of leukemia.

Indications

LuciDasa 50mg is indicated for:

• adults and children with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are in the chronic phase.
• adults with Ph+ CML that is chronic, rapid, or in the blast phase and who are intolerant of or resistant to previous treatments, such as imatinib mesylate.
• Adults and children with Ph+ acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy.

How to Take / Dosage

The dosing of LuciDasa 50mg varies based on the patient’s weight, age, and the specific condition being treated. It is typically administered once or twice daily, with or without food. The exact dosage and schedule should be determined by a healthcare professional, tailored to the individual patient’s needs.

Other Dosage Forms

Dasatinib is available in various strengths and formulations, including:

• Tablets of 20mg, 50mg, 70mg, 80mg, and 100mg.
• Oral suspension for pediatric patients or those who have difficulty swallowing tablets.
• The choice of dosage form and strength depends on the patient’s specific requirements and should be guided by a healthcare provider.

Side Effects

Common side effects of LuciDasa 50mg include:

• Low white blood cell count (neutropenia).
• Low platelet count (thrombocytopenia).
• Anemia.
• Fatigue.
• Headache.
• Rash
• Diarrhea.
• Nausea and vomiting.

Serious side effects may include:

• Pulmonary arterial hypertension (PAH).
• Bleeding or hemorrhage.
• Heart failure.
• QT interval prolongation on ECG.
• Patients should be monitored regularly for these potential adverse effects.

Storage

It is recommended to keep LuciDasa 50mg pills at room temperature, away from heat sources and moisture. To keep them safe from light and moisture, they should be stored in their original packaging. Keep out of children’s reach and carefully dispose of any unused medication.

Benefits

The primary benefits of LuciDasa 50mg include:

• Effective control of CML and Ph+ ALL, particularly in patients resistant or intolerant to other therapies.
• Oral administration offers convenience over intravenous chemotherapy.
• Targeted action reduces damage to normal cells, potentially leading to fewer side effects.

Prescription

LuciDasa 50mg is a prescription medication and should only be used under the supervision of a qualified healthcare professional. A thorough medical evaluation, including genetic testing for the Philadelphia chromosome, is necessary before initiating therapy.

Drug Interactions

Dasatinib can interact with other medications, including:

• Strong CYP3A4 inhibitors, such as clarithromycin and ketoconazole, may raise dasatinib levels.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease dasatinib levels.
• Other medications that affect blood clotting (e.g., warfarin) may increase the risk of bleeding.
• Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

FAQs

Can I cut or split LuciDasa 50mg tablets?

Do not cut, split, or crush LuciDasa 50mg tablets, as it may alter the dose and affect its effectiveness.

Can I take LuciDasa 50mg if I have liver or kidney problems?

Inform your doctor about any liver or kidney problems before taking LuciDasa 50mg, as dosage adjustments may be necessary.

How does LuciDasa 50mg work in the body?

LuciDasa 50mg inhibits the activity of specific tyrosine kinases, including BCR-ABL, to control the growth and survival of cancer cells in CML and Ph+ ALL.

What are the benefits of using LuciDasa 50mg?

The benefits of LuciDasa 50mg include effective control of CML and Ph+ ALL, oral administration convenience, and a targeted action that reduces damage to normal cells.

Conclusion

LuciDasa 50mg (dasatinib) represents a significant advancement in the treatment of Philadelphia chromosome-positive leukemia. Its targeted mechanism of action offers an effective alternative for patients, especially those who have not responded to other therapies. However, like all medications, it carries potential risks and side effects, necessitating careful monitoring by healthcare professionals. Patients should engage in open communication with their healthcare team to ensure the best possible outcomes while using LuciDasa.